No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
rucaparib Sensitive: A2 - Guideline
|
rucaparib Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
rucaparib Sensitive: A2 - Guideline
|
rucaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
rucaparib Sensitive: A2 - Guideline
|
rucaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
GTX Sensitive: A2 - Guideline
|
GTX Sensitive: A2 - Guideline
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
RET fusion
|
Pancreatic Adenocarcinoma
|
RET fusion
|
Pancreatic Adenocarcinoma
|
pralsetinib Sensitive: C1 - Off-label
|
pralsetinib Sensitive: C1 - Off-label
|
TMB-H
|
Pancreatic Adenocarcinoma
|
TMB-H
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
HER-2 expression
|
Pancreatic Adenocarcinoma
|
HER-2 expression
|
Pancreatic Adenocarcinoma
|
trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials
|
trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials
|
EGFR expression
|
Pancreatic Adenocarcinoma
|
EGFR expression
|
Pancreatic Adenocarcinoma
|
trastuzumab + erlotinib Sensitive: C3 – Early Trials
|
trastuzumab + erlotinib Sensitive: C3 – Early Trials
|
CDH1 expression
|
Pancreatic Adenocarcinoma
|
CDH1 expression
|
Pancreatic Adenocarcinoma
|
erlotinib + selumetinib Sensitive: C3 – Early Trials
|
erlotinib + selumetinib Sensitive: C3 – Early Trials
|
SMAD4 deletion
|
Pancreatic Adenocarcinoma
|
SMAD4 deletion
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials
|
TP53 mutation
|
Pancreatic Adenocarcinoma
|
TP53 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
TP53 mutation
|
Pancreatic Adenocarcinoma
|
TP53 mutation
|
Pancreatic Adenocarcinoma
|
FOLFOX Sensitive: C3 – Early Trials
|
FOLFOX Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
FOLFOX Sensitive: C3 – Early Trials
|
FOLFOX Sensitive: C3 – Early Trials
|
SEL1L-NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
SEL1L-NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
SEL1L-NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
SEL1L-NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Resistant: C4 – Case Studies
|
gemcitabine + albumin-bound paclitaxel Resistant: C4 – Case Studies
|
PD-L1 expression + TMB-H + FANCA deletion
|
Pancreatic Adenocarcinoma
|
PD-L1 expression + TMB-H + FANCA deletion
|
Pancreatic Adenocarcinoma
|
toripalimab Sensitive: C4 – Case Studies
|
toripalimab Sensitive: C4 – Case Studies
|
PD-L1 expression + TMB-H + FANCA deletion
|
Pancreatic Adenocarcinoma
|
PD-L1 expression + TMB-H + FANCA deletion
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: C4 – Case Studies
|
gemcitabine + albumin-bound paclitaxel Sensitive: C4 – Case Studies
|
EGFR exon 19 mutation
|
Pancreatic Adenocarcinoma
|
EGFR exon 19 mutation
|
Pancreatic Adenocarcinoma
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|
BRCA2 mutation + CHEK2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation + CHEK2 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: C4 – Case Studies
|
FOLFIRINOX Sensitive: C4 – Case Studies
|
BRCA2 1153insT
|
Pancreatic Adenocarcinoma
|
BRCA2 1153insT
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: C4 – Case Studies
|
cisplatin + gemcitabine Sensitive: C4 – Case Studies
|
BRCA1 mutation + TMB-H
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation + TMB-H
|
Pancreatic Adenocarcinoma
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRI Sensitive: C4 – Case Studies
|
FOLFIRI Sensitive: C4 – Case Studies
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
cobimetinib Sensitive: D – Preclinical
|
cobimetinib Sensitive: D – Preclinical
|
FAM83D overexpression
|
Pancreatic Adenocarcinoma
|
FAM83D overexpression
|
Pancreatic Adenocarcinoma
|
gemcitabine Resistant: D – Preclinical
|
gemcitabine Resistant: D – Preclinical
|
PTGR1 elevation + HRD
|
Pancreatic Adenocarcinoma
|
PTGR1 elevation + HRD
|
Pancreatic Adenocarcinoma
|
LP-184 Sensitive: D – Preclinical
|
LP-184 Sensitive: D – Preclinical
|
KRAS G13D
|
Pancreatic Adenocarcinoma
|
KRAS G13D
|
Pancreatic Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Adenocarcinoma
|
KRAS G12C
|
Pancreatic Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|